June 19-22, 2017 | San Diego, CA


Double Helix Sponsor


Schedule at a glance

Registration Rates

Join the Mailing List

Convention Content

Access reports, webinars, and recordings related to the BIO International Convention here!

Research Reports

*Latest Annual Report* 3rd Annual Emerging Therapeutic Company Investment and Deal Trends 2007-2016 

Request Your Copy Here  

More than 90% of our industry is made up of small companies. This report captures stats for companies with less than a $1 billion in sales and covers six main areas: venture funding, public investment (IPOs and follow-ons), licensing, M&A, and the clinical pipeline (partnered vs. partnered).



May 25 - Pharma Trends in Emerging Markets 

Learn more about the promise of emerging markets by looking at the activity and trends in the pharmaceutical industry in Brazil, Russia, India, China and South Korea (BRICS).

[Recording Available Soon]

May 16 - Applying Competitive Intelligence to Navigate the Changing Disease Landscape

In preparation for the 2017 BIO International Convention, Clarivate Analytics and BIO have teamed up to offer this free webinar where we will use neurodegenerative disease as a use case to demonstrate the critical information and analysis needed to be first in class and/or best in class for a therapy area. David Dunn, US Practice Lead and Scientific Advisor for Portfolio and Licensing, Clarivate Analytics will analyze the pipelines of three leading neurodegenerative diseases: Alzheimer’s, Parkinson’s and ALS. In this webinar David will examine current therapeutic hypotheses and the industry’s track record in finding therapies based on them.

[Recording Available Soon]

May 12 - Surfing the CNS Pipeline: Ripples, Swells, or Waves

While media attention tends to be focused upon CNS clinical misses, particularly when they involve Alzheimer’s disease modifying therapies, several CNS programs have recently generated data that portend paradigm shifts in the treatment of diseases with significant unmet need. Novel treatments have shown proof-of-concept and more in Spinal Muscular Atrophy, Super-Refractory Status Epilepticus, Rett Syndrome, Treatment-Resistant Depression, Progressive MS, and rare pediatric epilepsies. Looking forward, there are additional clinical-stage programs that promise to change the standard of care and reset the bar for compounds that follow (e.g., those of GW Pharma, Alder Pharma, AveXis, Quartet Medicine, Wave Life Sciences). This is in contrast to some high-profile programs which seem more likely to be additions to the current and still marginal standard of care than true clinical breakthroughs.

[View Webinar Recording Here]


BIO 2017 Local Guidebook

Explore everything that San Diego has to offer with our local guidebook, brought to you by Yelp! View Now.

  2017 Local Guidebook Image

Thank you to our 2017 Sponsors

Double Helix Sponsors

Helix Sponsors

Premier Sponsors